CISPLATINO SERVYCAL

Cisplatin 10 mg and 50 mg

LYOPHILIZED POWDER FOR INJECTION

Sale under filed prescription

Made in Argentina

QUALI-QUANTITATIVE COMPOSITION:
Each vial of Cisplatino Servycal 10 mg contains:
Cisplatin 10mg
Mannitol 100 mg
Sodium chloride 90 mg
Hydrochloric acid q.s. to adjust pH 3.4
Each vial of Cisplatino Servycal 50 mg contains:
Cisplatin 50 mg
Mannitol 500 mg
Sodium chloride 450 mg
Hydrochloric acid q.s. to adjust pH 3.4

THERAPEUTIC ACTION:
Antineoplastic.

INDICATIONS:
Metastatic testicular tumors:
In combination therapy with other approved chemotherapeutic agent in patients with metastatic testicular tumors who have received appropriate surgery and/or radiotherapeutic procedures.

Metastatic ovarian tumors:
In combination therapy with other approved chemotherapeutic agent in patients with metastatic ovarian tumors who have received appropriate surgery. The combination consists of cisplatin and cyclophosphamide. Cisplatin as single agent is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin therapy.

Advanced bladder cancer:
Cisplatin is indicated as single agent in patients with bladder cancer which is no longer amenable to surgery and/or radiotherapy.

PRESENTATION:
Cisplatino Servycal 10 and 50 mg, carton with 1 vial containing lyophilized powder.

Keep between 15 ºC and 25 ºC, avoiding exposure to temperatures below 5 ºC.

Protect from light.